Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1590-1608

  Lee, Mary ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Erectile dysfunction; Phosphodiesterase inhibitor; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENDROFLUMETHIAZIDE; CARVEDILOL; CIMETIDINE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; GLYCERYL TRINITRATE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LABETALOL; METOPROLOL; PHOSPHODIESTERASE V; PROCAINAMIDE; PROSTAGLANDIN E1; QUINIDINE; RITONAVIR; SAQUINAVIR; SILDENAFIL; SOTALOL; TADALAFIL; TESTOSTERONE; VARDENAFIL;

ABNORMAL VISION; ARTERIOSCLEROSIS; BACKACHE; BEDTIME DOSAGE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HAZARD RATIO; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; LOWER URINARY TRACT SYMPTOM; MALE; MEDLINE; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; SIDE EFFECT;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ERECTILE DYSFUNCTION; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

EID: 82855162720     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.029     Document Type: Review

References (90)

1. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54-61.
2. Bacon C.G., Mittleman M.A., Kawachi I., et al. Sexual function in men older than 50 years of age: results from the Health Professionals Follow-Up Study. Ann Intern Med 2003, 139:161-168.
3. Montague D.K., Jarow J.P., Broderick G.A., et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005, 174:230-239. 5.
4. Qaseem A., Snow V., Denberg T.D., et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2009, 151:639-649.
5. Kubin M., Wagner G., Fagl-Meyer A.R. Epidemiology of erectile dysfunction. Intern J Impot Res 2003, 15:63-71.
6. O'Keefe, Hunt D.K. Assessment and treatment of impotence. Med Clin North Am 1995, 79:415-434.
7. Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009, 84:139-148.
8. Tsertsvadze A., Fink H.A., Yazdi F., et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009, 151:650-661.
9. Fink H.A., Mac Donald R., Rutks I.R., et al. Sildenafil for male erectile dysfunction. Arch Intern Med 2002, 162:1349-1360.
10. Eardley I., Lee J.C., Shabsign R., et al. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med 2010, 7:244-255.
11. Carson C.C. Phosphodiesterase type 5 inhibitors: state of the therapeutics class. Urol Clin North Am 2007, 34:507-515.
12. Carson C.C., Burnett A.L., Levine L.A., et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002, 60(Suppl 2B):12-27.
13. McMahon C.N., Smith C.J., Shabsign R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006, 332:589-592.
14. Eardley I., Mirone V., Montorsi F., et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. BJU Int 2005, 96:1323-1332.
15. von Keitz A., Rajfer J., Segal S., et al. A multicenter, randomized, double-blind crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004, 45:499-507.
16. Govier F., Potempa A.J., Kaufman J., et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003, 25:2709-2723.
17. Tolra J.R., Campana J.M., Ciutat L.F., et al. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006, 3:901-909.
18. Kendirci M., Tanriverdi O., Trost L., et al. Management of sildenafil treatment failures. Curr Opin Urol 2006, 16:449-459.
19. Montorsi F., Nathan H.P., McCullough A., et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004, 172:1036-1041.
20. Morelli A., Filippi S., Mancini R., et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinol 2004, 145:2253-2263.
21. Mirone V., Fusco F., Rossi A., et al. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int 2009, 103:1212-1217.
22. Shabsigh R., Seftel A.D., Rosen R.C., et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology 2006, 68:689-696.
23. Cialis [package insert] 2011, Eli Lilly, Indianapolis, IN.
24. Gruenwald I., Leiba R., Vardi Y. Effect of sildenafil on middle-aged sexually active males with no erectile complaints: a randomized placebo-controlled double-blind study. Eur Urol 2009, 55:969-978.
25. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005, 96:313-321.
26. Viagra [package insert] 2011, Pfizer Inc, New York, NY.
27. Levitra [package insert] 2011, Bayer Health Care Pharmaceuticals, Wayne, NJ.
28. Rajogopalan P., Mazzu A., Xia C., et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003, 43:260-267.
29. Helstrom W.J.G. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. Int J Clin Pract 2007, 61:1547-1554.
30. Carson C.C. Long-term use of sildenafil. Expert Opin Pharmacother 2003, 4:397-495.
31. Moncada I., Jara J., Subira D., et al. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 2004, 46:357-360.
32. McCullough A.R., Steidle C.P., Klee B., et al. Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. Urology 2008, 71:686-692.
33. Porst H., Padma-Nathan H., Giuliano F., et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003, 62:121-126.
34. Schwartz E.J., Wong P., Graydon R.J. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004, 171:771-774.
35. Eardley I. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders.". Eur Urol 2006, 50:31-33.
36. Vardi Y., Appel B., Offer Y., et al. Effect of chronic sildenafil on penile endothelial function: a randomized, double-blind, placebo-controlled study. J Urol 2009, 182:2850-2855.
37. Sommer F., Schulza W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol 2005, 23:385-392.
38. Raina R., Pahlajani G., Agarwal A., et al. Early penile rehabilitation following radical prostatectomy: Cleveland Clinic experience. Int J Impot Res 2008, 20:121-126.
39. Padma-Nathan I.I., McCullough A.R., Levine A.R., et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008, 20:479-486.
40. McCullough A.R., Levina L.A., Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled triad. J Sex Med 2008, 5:476-484.
41. Hatzimouratidis K., Burnett A.L., Hatzichristou D., et al. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009, 55:334-347.
42. Porst H., Giuliano F., Glina S., et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006, 50:351-359.
43. Rajfer J., Aliotta P.J., Steidle C.P., et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007, 19:95-103.
44. Hatzichristou D., Gambla M., Rubio-Aurioles E., et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008, 25:138-146.
45. Porst H., Rajfer J., Casabe A.D., et al. Long term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008, 5:2160-2169.
46. Zumbe J., Porst H., Sommer F., et al. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol 2008, 54:204-212.
47. Seftel A., Goldfischer E., Kim E.D., et al. Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. J Urol 2011, 185:243-248.
48. Donatucci C.F., Wong D.G., Giuliano F., et al. Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin 2008, 24:3383-3392.
49. Kloner R.A. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on α-blocker interactions. Am J Cardiol 2005, 96(12B Suppl):42M-46M.
50. Olsson A.M., Persson C.A. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 2001, 55:171-176.
51. Haztimouratidis K. Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?. Curr Urol Rep 2007, 8:482-490.
52. Laties A., Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006, 3:12-27.
53. Hattenhauer M.G., Leavitt J.A., Hodge D.O., et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997, 123:103-107.
54. Danesh-Meyer H.V., Levin L.A. Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association. Br J Ophthalmol 2007, 91:1551-1555.
55. Dundar S.O. Visual loss associated with erectile dysfunction drugs. Can J Ophthalmol 2007, 42:10-12.
56. Gorkin L., Hvidsten K., Sobel R.E., Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006, 60:500-503.
57. Salomon O., Huna-Baron R., Steinberg D.M., et al. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye 1999, 13(Pt 3A):357-359.
58. Maddox P.T., Saunders J., Chandrasekhar S.S. Sudden hearing loss from PDE-5 inhibitors: a possible cellular stress etiology. Laryngoscope 2009, 119:1586-1589.
59. Okuyugu S., Guven O.E., Akoglu E. Effect of phosphodiesterase-5 inhibitor on hearing. J Laryngol Otol 2009, 123:718-732.
60. Snodgrass A.J., Campbell H.M., Mace D.L., et al. Sudden sensorineural hearing loss associated with vardenafil. Pharmacotherapy 2010, 30:112.
61. Atiemo H.O., Szostak M.J., Sklar G.N. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003, 170:2356-2358.
62. McCullough A.R., Barada J.H., Fawzy A., et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002, 60(Suppl 2B):28-38.
63. Meuleman E., Cuzin B., Opsomer R.J., et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 2001, 87:75-81.
64. McCullough A.R., Kaminetsky J.C., Crowley A.R., et al. Early sildenafil optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. Int J Impot Res 2007, 19:154-160.
65. Raina R., Agarwal A., Allamaneni S.S., et al. Sildenafil citrate and vacuum device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 2005, 65:350-364.
66. Steers W.D. Viability and safety of combination drug therapies for erectile dysfunction. J Urol 2003, 170(2 Pt 2):S20-S23.
67. Morelli A., Corona G., Filippi S., et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy?. J Endocrinol Invest 2007, 30:880-888.
68. Haren M., Chapman I., Coates P., et al. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Aging 2005, 34:125-130.
69. Cavallini G., Caracciolo S., Vitali G., et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004, 63:641-646.
70. Rabkin J.G., Wagner G.J., Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000, 57:141-147.
71. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002, 8:440-456. AACE Hypogonadism Task Force.
72. McMahon C.G. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res 2002, 14:533-536.
73. Brisson T.E., Broderick G.A., Thiel D.D., et al. Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. Urology 2006, 68:397-401.
74. Jackson G., Montorsi P., Cheitlin M.D. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology 2006, 68(Suppl 3A):47-60.
75. Jackson G., Benjamin N., Jackson N., et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999, 83:13C-20C.
76. Corona G., Razzoli E., Forti G., et al. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008, 31:799-808.
77. Kloner R.A., Mitchell M., Emmick J.T. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003, 92(9A):47M-57M.
78. Kloner R.A., Sadovsky R., Johnson E.G., et al. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res 2005, 17:450-454.
79. Bohm M., Burkart M., Baumann G. Sildenafil is well tolerated by erectile dysfunction patients taking antihypertensive medications, including those on multidrug regimens. Curr Drug Saf 2007, 2:5-8.
80. van Ahlen H., Wahle K., Kupper W., et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005, 2:856-864.
81. Thompson I.M., Tangen C.M., Goodman P.J., et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005, 294:2996-3002.
82. Kapur V., Chien C.V., Fuess J.E., et al. The relationship between erectile dysfunction and cardiovascular disease. Part II: the role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med 2008, 9:187-195.
83. Inman B.A., St.Sauver J.L., Jacobson D.J., et al. A population-based longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009, 84:108-113.
84. Schouten B.W., Bohnen A.M., Bosch J.L., et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res 2008, 20:92-99.
85. Kloner R.A., Hutter A.M., Emmick J.T., et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003, 42:1855-1860.
86. Dmochowski R., Roehrborn C., Klise S., et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12 week clinical trial. J Urol 2010, 183:1092-1097.
87. Oger S., Behr-Roussel D., Gorny D., et al. Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 2010, 57:699-707.
88. McVary K.T., Monnig W., Camps J.L., et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007, 177:1071-1077.
89. Roehrborn C.G., McVary K.T., Elion-Mboussa A., et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008, 180:1228-1234.
90. Bechara A., Romano S., Casabe A., et al. Comparative efficacy assessment of tamsulosin vs tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008, 5:2170-2178.